A Multicenter Cancer Biospecimen Collection Study

Part of paid clinical trials in San Francisco, California.

Sponsor
Cofactor Genomics, Inc.
Study ID
NCT04510129
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • OncoPrism™ assay — DIAGNOSTIC_TEST
    OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.

Study Details

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.

Key Dates

Start date
Feb 5, 2020
Status verified
Mar 2025
Primary completion
Feb 28, 2027
Completion
Feb 28, 2027

Study Design

Enrollment
1,650 participants (estimated)

Arms

  • Arm: head and neck squamous cell carcinoma (HNSCC)
  • Arm: non-small-cell lung cancer (NSCLC)
  • Arm: small cell lung cancer (SCLC)
  • Arm: urothelial carcinoma (UCC)
  • Arm: gastric or gastroesophageal junction adenocarcinoma
  • Arm: cervical cancer
  • Arm: esophageal squamous cell carcinoma (ESCC)
  • Arm: triple-negative breast cancer (TNBC)
  • Arm: hepatocellular carcinoma (HCC)
  • Arm: renal cell carcinoma (RCC)
  • Arm: colorectal cancer (CRC)

Primary Outcome Measure

PD-L1/PD-1 inhibitor response [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
CurebaseSan FranciscoCalifornia94131
Study Director
[email protected]
(628) 200-4082

Find similar trials in San Francisco, CA

By condition
Cervical cancerColorectal cancerLiver cancerKidney cancerBreast cancerBladder cancer
By specialty
OncologyGynecologic oncologyWomen's healthGI oncologyHepatologyUrologyBreast oncology
By research site
Curebase· San Francisco, CA

Related Studies